A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients with Recurring Uterine Cancer

Trial status:Will Be Recruiting
Study Identifier:
BNT323-01
ClinicalTrials.gov Identifier:
NCT06340568
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Will Be Recruiting

Trial details

Medical Condition
  • Endometrial Cancer
    • Study Drug
  • Drug: BNT323/DB-1303
  • Drug: Doxorubicin
  • Drug: Paclitaxel
    • Phase
    Phase 3
    Sex
    Female
    Age
    18+
    Estimated Trial Date
    Nov 2024 - May 2027

    Protocol summary

    The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population.

    Trial locations

    No locations found.